{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:19:37Z","timestamp":1792279177488,"version":"4.4.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Subcutaneous infliximab (SC-IFX) offers an alternative to intravenous infliximab (IV-IFX) in adults with inflammatory bowel disease (IBD), but evidence in children is scarce. This study reports treatment persistence, tolerability, and pharmacokinetics in a real-world pediatric IBD cohort following transition from IV-IFX.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single center retrospective study including all pediatric IBD patients transitioned from IV-IFX to SC-IFX (120\u00a0mg every other week) at our institution between November 2023 and April 2025. Clinical disease activity scores, inflammatory markers, IFX serum concentrations, and anti-IFX antibodies (AIA) were assessed at baseline and during follow-up. The primary outcome was treatment persistence. Secondary outcomes included disease activity, pharmacokinetics, immunogenicity and tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty patients (median age 14.5 years; range 5\u201317), including six children\u2009&lt;\u200912 years and five weighing\u2009&lt;\u200940\u00a0kg, were included. After a median observation period of 44 weeks (IQR 26\u201360), 16\/20 patients (80%) remained on SC-IFX, with no significant difference between Crohn\u2019s disease and ulcerative colitis. In a subgroup of four patients who received SC-IFX as a third dose following two intravenous induction doses, 3\/4 (75%) maintained treatment over a median observation period of 60 weeks (range 16\u201364 weeks) and remained in clinical remission during follow-up. IFX serum concentrations increased after switching (median 11.8\u00a0\u00b5g\/mL pre-switch vs. \u226524\u00a0\u00b5g\/mL at follow-up), with most follow-up measurements reaching the assay ceiling. Concentrations were descriptively comparable between weight groups. All patients with detectable AIA prior to switching became antibody-negative during SC-IFX therapy, and no de novo antibodies were observed. Two patients discontinued therapy due to worsening of pre-existing paradoxical psoriasis. No other adverse events were documented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SC-IFX showed high persistence, stable inflammatory markers and good tolerability in this pediatric cohort, including younger and lower-weight children. SC-IFX appears to be a feasible maintenance option in selected pediatric patients, including early use after induction. Prospective studies are warranted to define pediatric-specific pharmacokinetic targets and individualized dosing strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40348-026-00251-2","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T02:48:44Z","timestamp":1784256524000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Subcutaneous infliximab as a maintenance option in pediatric IBD: a real-world cohort including younger and lower-weight children"],"prefix":"10.1186","volume":"13","author":[{"given":"Neele","family":"Ridder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Overberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Kalveram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samipa","family":"Pudasaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ruppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Schumm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Henning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Bufler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"4","key":"251_CR1","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2021.12.282","volume":"162","author":"ME Kuenzig","year":"2022","unstructured":"Kuenzig ME, Fung SG, Marderfeld L, Mak JWY, Kaplan GG, Ng SC et al (2022) Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease. Syst Rev Gastroenterol 162(4):1147\u20131159e4. https:\/\/doi.org\/10.1053\/j.gastro.2021.12.282","journal-title":"Syst Rev Gastroenterol"},{"issue":"3","key":"251_CR2","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","volume":"132","author":"J Hyams","year":"2007","unstructured":"Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J et al (2007) Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u2019s disease in children. Gastroenterology 132(3):863\u2013873 quiz 1165-6. https:\/\/doi.org\/10.1053\/j.gastro.2006.12.003","journal-title":"Gastroenterology"},{"issue":"2","key":"251_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/mpg.0000000000002035","volume":"67","author":"D Turner","year":"2018","unstructured":"Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J et al (2018) Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn\u2019s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 67(2):257\u2013291. https:\/\/doi.org\/10.1097\/mpg.0000000000002035","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"251_CR4","doi-asserted-by":"publisher","unstructured":"van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL et al (2021) The Medical Management of Paediatric Crohn\u2019s Disease: an ECCO-ESPGHAN Guideline Update. J Crohns Colitis 15(2). https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa161","DOI":"10.1093\/ecco-jcc\/jjaa161"},{"issue":"3","key":"251_CR5","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/jpn3.70097","volume":"81","author":"E Wine","year":"2025","unstructured":"Wine E, Aloi M, Van Biervliet S, Bronsky J, di Carpi JM, Gasparetto M et al (2025) Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn\u2019s and Colitis Organisation. J Pediatr Gastroenterol Nutr 81(3):765\u2013815. https:\/\/doi.org\/10.1002\/jpn3.70097","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"9","key":"251_CR6","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1093\/ecco-jcc\/jjae059","volume":"18","author":"JD Chetwood","year":"2024","unstructured":"Chetwood JD, Tran Y, Subramanian S, Smith PJ, Iborra M, Buisson A et al (2024) Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. J Crohns Colitis 18(9):1440\u20131449. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae059","journal-title":"J Crohns Colitis"},{"issue":"9","key":"251_CR7","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/ecco-jcc\/jjac053","volume":"16","author":"PJ Smith","year":"2022","unstructured":"Smith PJ, Critchley L, Storey D, Gregg B, Stenson J, Kneebone A et al (2022) Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study. J Crohns Colitis 16(9):1436\u20131446. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac053","journal-title":"J Crohns Colitis"},{"issue":"8","key":"251_CR8","doi-asserted-by":"publisher","first-page":"102680","DOI":"10.1016\/j.clinre.2025.102680","volume":"49","author":"AS Duquerois","year":"2025","unstructured":"Duquerois AS, Martinez-Vinson C, Loppinet T, Restier L, Poinsot P, Portefaix A et al (2025) A series of pediatric patients with inflammatory bowel disease switching from intravenous to subcutaneous infliximab maintenance therapy. Clin Res Hepatol Gastroenterol 49(8):102680. https:\/\/doi.org\/10.1016\/j.clinre.2025.102680","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"2","key":"251_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/mpg.0000000000003838","volume":"77","author":"L Gianolio","year":"2023","unstructured":"Gianolio L, Armstrong K, Swann E, Shepherd R, Henderson P, Wilson DC et al (2023) Effectiveness of Switching to Subcutaneous Infliximab in Pediatric Inflammatory Bowel Disease Patients on Intravenous Maintenance Therapy. J Pediatr Gastroenterol Nutr 77(2):235\u2013239. https:\/\/doi.org\/10.1097\/mpg.0000000000003838","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"251_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaf335","author":"EH Boute","year":"2026","unstructured":"Boute EH, Gianolio L, Mahmmod S, Pochesci S, Armstrong K, Henderson P et al (2026) Persistence and safety of subcutaneous infliximab up to 1 year after switching from intravenous infliximab in pediatric inflammatory bowel disease: a multicenter real-world cohort study. Inflamm Bowel Dis. https:\/\/doi.org\/10.1093\/ibd\/izaf335","journal-title":"Inflamm Bowel Dis"},{"key":"251_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/jpn3.70267","author":"JA Eldredge","year":"2025","unstructured":"Eldredge JA, Kaur R, Chua CW, Chidgey T, Tano M, Singh N et al (2025) Subcutaneous infliximab use in children with inflammatory bowel disease in an Australian center. J Pediatr Gastroenterol Nutr. https:\/\/doi.org\/10.1002\/jpn3.70267","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"7","key":"251_CR12","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","volume":"160","author":"S Schreiber","year":"2021","unstructured":"Schreiber S, Ben-Horin S, Leszczyszyn J, Dudkowiak R, Lahat A, Gawdis-Wojnarska B et al (2021) Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. Gastroenterology 160(7):2340\u20132353. https:\/\/doi.org\/10.1053\/j.gastro.2021.02.068","journal-title":"Gastroenterology"},{"issue":"1","key":"251_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/apt.16852","volume":"56","author":"X Roblin","year":"2022","unstructured":"Roblin X, Veyrard P, Bastide L, Berger AE, Barrau M, Paucelle AS et al (2022) Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn\u2019s disease. Aliment Pharmacol Ther 56(1):77\u201383. https:\/\/doi.org\/10.1111\/apt.16852","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"251_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/s0022-3476(78)80601-5","volume":"93","author":"GB Haycock","year":"1978","unstructured":"Haycock GB, Schwartz GJ, Wisotsky DH (1978) Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr 93(1):62\u201366. https:\/\/doi.org\/10.1016\/s0022-3476(78)80601-5","journal-title":"J Pediatr"},{"issue":"9","key":"251_CR15","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1093\/ibd\/izy112","volume":"24","author":"S Sridhar","year":"2018","unstructured":"Sridhar S, Maltz RM, Boyle B, Kim SC (2018) Dermatological Manifestations in Pediatric Patients with Inflammatory Bowel Diseases on Anti-TNF Therapy. Inflamm Bowel Dis 24(9):2086\u20132092. https:\/\/doi.org\/10.1093\/ibd\/izy112","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"251_CR16","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/ecco-jcc\/jjad188","volume":"18","author":"X Roblin","year":"2024","unstructured":"Roblin X, Nancey S, Papamichael K, Duru G, Flamand M, Kwiatek S et al (2024) Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel Disease. J Crohns Colitis 18(5):679\u2013685. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad188","journal-title":"J Crohns Colitis"},{"issue":"3","key":"251_CR17","doi-asserted-by":"publisher","first-page":"485","DOI":"10.14309\/ajg.0000000000002096","volume":"118","author":"AS Cheifetz","year":"2023","unstructured":"Cheifetz AS, Vande Casteele N, Wang Z, Dubinsky MC, Papamichael K (2023) Higher Postinduction Infliximab Concentrations Are Associated With Favorable Clinical Outcomes in Pediatric Crohn\u2019s Disease: A Post Hoc Analysis of the REACH Trial. Am J Gastroenterol 118(3):485\u2013490. https:\/\/doi.org\/10.14309\/ajg.0000000000002096","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"251_CR18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s13318-025-00959-y","volume":"50","author":"RA Weersink","year":"2025","unstructured":"Weersink RA, Keizer RJ, Derijks LJJ (2025) Simulated Dosing Regimens of Subcutaneous Infliximab in Adults and Children with Inflammatory Bowel Disease: Exploring Switch and Initiation Strategies. Eur J Drug Metab Pharmacokinet 50(5):419\u2013430. https:\/\/doi.org\/10.1007\/s13318-025-00959-y","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"4","key":"251_CR19","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/apt.17822","volume":"59","author":"A Buisson","year":"2024","unstructured":"Buisson A, Nachury M, Bazoge M, Yzet C, Wils P, Dodel M et al (2024) Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT study. Aliment Pharmacol Ther 59(4):526\u2013534. https:\/\/doi.org\/10.1111\/apt.17822","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"251_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cgh.2025.03.021","volume":"24","author":"SI Anjie","year":"2026","unstructured":"Anjie SI, Gecse KB, Meloni CM, Vidal-Itriago A, L\u00f6wenberg M, D\u2019Haens GR (2026) Immunogenicity and Efficacy of Subcutaneous Infliximab Monotherapy vs Combination Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 24(1):57\u201368e5. https:\/\/doi.org\/10.1016\/j.cgh.2025.03.021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"251_CR21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3389\/fimmu.2020.00312","volume":"11","author":"S Atiqi","year":"2020","unstructured":"Atiqi S, Hooijberg F, Loeff FC, Rispens T, Wolbink GJ (2020) Immunogenicity of TNF-Inhibitors. Front Immunol 11:312. https:\/\/doi.org\/10.3389\/fimmu.2020.00312","journal-title":"Front Immunol"},{"issue":"2","key":"251_CR22","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/ecco-jcc\/jjab140","volume":"16","author":"E Crowley","year":"2022","unstructured":"Crowley E, Ma C, Andic M, Feagan BG, Griffiths AM, Jairath V (2022) Impact of Drug Approval Pathways for Paediatric Inflammatory Bowel Disease. J Crohns Colitis 16(2):331\u2013335. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab140","journal-title":"J Crohns Colitis"}],"container-title":["Molecular and Cellular Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-026-00251-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40348-026-00251-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-026-00251-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T02:48:45Z","timestamp":1784256525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40348-026-00251-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["251"],"URL":"https:\/\/doi.org\/10.1186\/s40348-026-00251-2","relation":{},"ISSN":["2194-7791"],"issn-type":[{"value":"2194-7791","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"14 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethics committee of the Charit\u00e9 \u2013 Universit\u00e4tsmedizin under EA2\/094\/25.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"38"}}